A randomized controlled trial to assess the efficacy and safety of doubling dose clopidogrel versus ticagrelor for the treatment of acute coronary syndrome in patients with CYP2C19*2 homozygotes.

about

The Daniel K. Inouye College of Pharmacy Scripts: Precision Medicine Through the Use of Pharmacogenomics: Current Status and Barriers to Implementation

P2860

Q41433207-58BEC3B9-BC6D-4C31-A776-98CE676C1340

P2860

A randomized controlled trial to assess the efficacy and safety of doubling dose clopidogrel versus ticagrelor for the treatment of acute coronary syndrome in patients with CYP2C19*2 homozygotes.

Item

http://www.wikidata.org/entity/Q41895739

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A randomized controlled trial ...... ts with CYP2C19*2 homozygotes.

@en

type

Item

label

A randomized controlled trial ...... ts with CYP2C19*2 homozygotes.

@en

prefLabel

A randomized controlled trial ...... ts with CYP2C19*2 homozygotes.

@en

P1476

A randomized controlled trial ...... ts with CYP2C19*2 homozygotes.

@en

P2093

Jiang Li

http://www.w3.org/2001/XMLSchema#string

Liying Chen

http://www.w3.org/2001/XMLSchema#string

Ran Xiong

http://www.w3.org/2001/XMLSchema#string

Shangqiu Ning

http://www.w3.org/2001/XMLSchema#string

Tieduo Kang

http://www.w3.org/2001/XMLSchema#string

Wenxian Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial

Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: evidence from a meta-regression

Variable platelet response to aspirin and clopidogrel in atherothrombotic disease

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.

First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.

CYP2C19 and ABCB1 gene polymorphisms are differently distributed according to ethnicity in the Brazilian general population.

Comparison of Adjunctive Naoxintong versus Clopidogrel in Volunteers with the CYP2C19*2 Gene Mutation Accompanied with Qi Deficiency and Blood Stasis Constitution

Genetic determinants of response to clopidogrel and cardiovascular events.

Cytochrome p-450 polymorphisms and response to clopidogrel.

P304

13310-13316

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26550258

http://www.w3.org/2001/XMLSchema#string

P921

clopidogrel

P932

4612943

http://www.w3.org/2001/XMLSchema#string

A randomized controlled trial to assess the efficacy and safety of doubling dose clopidogrel versus ticagrelor for the treatment of acute coronary syndrome in patients with CYP2C19*2 homozygotes.

about

P2860

P2860

A randomized controlled trial to assess the efficacy and safety of doubling dose clopidogrel versus ticagrelor for the treatment of acute coronary syndrome in patients with CYP2C19*2 homozygotes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P921

P932

P1433

P1476

P2093

P2860

P304

P31

P433

P478

P577

P698

P921

P932